Shortening TB Treatment

The problem this research is trying to solve

TB is caused by Mycobacterium tuberculosis (Mtb) and, even when the strain is fully drug-susceptible, treatment typically lasts six months. This long duration is not accidental. TB bacteria can survive inside macrophages—immune cells meant to destroy infections—by slowing their own activity and entering a state in which antibiotics work poorly. Eliminating these slow-growing bacteria requires extended therapy.

This prolonged treatment increases the risk of missed doses, treatment dropout, and ultimately drug resistance, making TB harder to control globally.

What this study found

The researchers examined how macrophage energy metabolism affects TB’s ability to tolerate drugs. Macrophages generate energy mainly in two ways:

• Oxidative phosphorylation (OXPHOS): a mitochondrial process associated with low oxidative stress.
• Glycolysis: a glucose-based pathway that produces higher oxidative stress.

The study found that when macrophages rely more on glycolysis, TB bacteria inside them become more oxidised, experience greater metabolic stress, and are far more vulnerable to frontline TB drugs. In contrast, macrophages dominated by OXPHOS create a low-stress environment in which TB bacteria remain chemically reduced and more drug-tolerant.

A key regulator of this process is NRF2, a host protein that dampens oxidative stress. Higher NRF2 activity keeps macrophages in an OXPHOS-heavy state that inadvertently shelters TB bacteria. Reducing NRF2 activity shifts macrophages toward glycolysis, increases oxidative stress, and weakens bacterial drug tolerance.

The “old drug, new role” angle

To test whether this metabolic shift could be achieved using existing medicines, the researchers examined meclizine, a widely used and inexpensive drug commonly prescribed for motion sickness. In laboratory experiments and mouse models of TB infection, meclizine pushed infected macrophages toward glycolysis and, when combined with standard TB antibiotics, produced a substantially greater reduction in bacterial burden than antibiotics alone. The study reported no harmful interactions between meclizine and frontline TB drugs in these experimental settings.

Why it matters (and what it does not yet mean)

This research advances the concept of host-directed therapy—treating the patient’s cellular environment alongside the infection itself. By preventing TB bacteria from entering drug-tolerant states inside immune cells, existing antibiotics may work faster and more effectively.

Importantly, the findings are preclinical and do not alter current treatment guidelines. Standard six-month TB regimens remain essential. However, the study provides a clear biological explanation for TB’s persistence and a credible scientific pathway toward shorter, more effective treatments in the future. 

Long TB treatments burden patients and health systems and increase resistance risk. If host-directed strategies can safely shorten treatment by making bacteria less tolerant to drugs, they could significantly improve TB control worldwide—using therapies that are already familiar and affordable.